Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimization of MSC therapeutic strategies for improved GVHD treatment

Optimization of MSC therapeutic strategies for improved GVHD treatment AbstractMesenchymal stem cells (MSCs) have a powerful immunosuppressive capacity, and they have been used to treat numerous immune diseases, such as refractory graft-versus-host disease. Nevertheless, there are conflicting clinical data. To our knowledge, MSCs from different donors do not share the same qualities and have different immunosuppressive capacities. Infused MSCs are cleared by the recipient’s immune cells or macrophages. Therefore, the MSC therapeutic strategy might be the most important factor that determines treatment success. Repeated infusions would lead to a relatively stable MSC concentration, which would benefit a sustained therapeutic effect. In this review, we focus on the quality of MSCs and the associated therapeutic strategy, as well as other potential variables affecting their utility as a cellular pharmaceutical. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infection International de Gruyter

Optimization of MSC therapeutic strategies for improved GVHD treatment

Wang, Hanyu; Kuang, Weihong
Infection International , Volume 6 (1): 7 – Nov 28, 2017
Download PDF
7 pages

Loading next page...
 
/lp/de-gruyter/optimization-of-msc-therapeutic-strategies-for-improved-gvhd-treatment-G9PITyOCV2
Publisher
de Gruyter
Copyright
© 2017 Walter de Gruyter GmbH, Berlin/Boston
eISSN
2544-0349
DOI
10.1515/ii-2017-0151
Publisher site
See Article on Publisher Site

Abstract

AbstractMesenchymal stem cells (MSCs) have a powerful immunosuppressive capacity, and they have been used to treat numerous immune diseases, such as refractory graft-versus-host disease. Nevertheless, there are conflicting clinical data. To our knowledge, MSCs from different donors do not share the same qualities and have different immunosuppressive capacities. Infused MSCs are cleared by the recipient’s immune cells or macrophages. Therefore, the MSC therapeutic strategy might be the most important factor that determines treatment success. Repeated infusions would lead to a relatively stable MSC concentration, which would benefit a sustained therapeutic effect. In this review, we focus on the quality of MSCs and the associated therapeutic strategy, as well as other potential variables affecting their utility as a cellular pharmaceutical.

Journal

Infection International – de Gruyter

Published: Nov 28, 2017

References

  • Genzyme backs Osiris, despite Prochymal flop
  • Functional heterogeneity of mesenchymal stem cells: implications for cell therapy
  • Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis
  • Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density
  • Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease
  • Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation
  • Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease
  • Are mesenchymal stem cells major sources of safe signals in immune system?
  • Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
  • Allogeneic hematopoietic stem cell transplantation: complications and results
  • Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis
  • Intraperitoneal injection (IP), Intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis
  • Aging of mesenchymal stem cells
  • Mesenchymal stem cells are injured by complement after their contact with serum
  • How I treat refractory acute GVHD
  • Mesenchymal stem cells and haematopoietic stem cell transplantation
  • Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells
  • Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time
  • Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide
  • Are therapeutic human mesenchymal stromal cells compatible with human blood?
  • Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
  • Survival after mesenchymal stromal cell therapy in steroid - refractory acute graft - versus - host disease systematic review and meta - analysis
    Hashmi
  • Senescence is heterogeneous in mesenchymal stromal cells: kaleidoscopes for cellular aging
  • Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
  • Mesenchymal stem cells: a double-edged sword in regulating immune responses
  • Doubts over heart stem-cell therapy
  • Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
  • Functional heterogeneity of mesenchymal stem cells: implications for cell therapy
  • Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning
  • Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
  • Galipeau, J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
  • Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes
  • Kde Effects of high - dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients
    Prata
  • Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion
  • Age-related impairment of mesenchymal progenitor cell function
  • Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation
  • Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy?
  • Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow
  • Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
  • Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy?
  • Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease
  • IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
  • Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
  • A survey of diagnosis, management, and grading of chronic GVHD
  • Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion
  • Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
  • Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
  • Age-related impairment of mesenchymal progenitor cell function
  • Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy
  • Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice
  • Modification of mesenchymal stem cells for cardiac regeneration
  • No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
  • No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
  • Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients
  • Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and Entecavir: a 24-month prospective study
  • Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
  • Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow
  • Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing
  • Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart
  • Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients
  • Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms
  • Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation
  • The mesenchymal stromal cells dilemma – does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
  • Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
  • How I treat refractory acute GVHD
  • Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
  • Senescence is heterogeneous in mesenchymal stromal cells: kaleidoscopes for cellular aging
  • Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease
  • Allogeneic hematopoietic stem cell transplantation: complications and results
  • Are mesenchymal stem cells major sources of safe signals in immune system?
  • Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry
  • Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots
  • Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion
  • Aging of mesenchymal stem cells
  • Different facets of aging in human mesenchymal stem cells
  • IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
  • Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation
  • Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis
  • Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing
  • The mesenchymal stromal cells dilemma – does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
  • Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis
  • Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation
  • Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study
  • Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and Entecavir: a 24-month prospective study
  • Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots
  • Mesenchymal stromal cell ‘licensing’: a multistep process
  • Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation
  • Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
  • Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms
  • Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide
  • Genzyme backs Osiris, despite Prochymal flop
  • Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice
  • Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
  • Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
  • Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice
  • Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies
  • Are therapeutic human mesenchymal stromal cells compatible with human blood?
  • Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry
  • Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells
  • Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time
  • Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
  • Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies
  • Mesenchymal stem cells and haematopoietic stem cell transplantation
  • Survival after mesenchymal stromal cell therapy in steroid - refractory acute graft - versus - host disease systematic review and meta - analysis
    Hashmi
  • Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
  • Mesenchymal stem cells: a double-edged sword in regulating immune responses
  • Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
  • Kde Effects of high - dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients
    Prata
  • Mesenchymal stromal cell ‘licensing’: a multistep process
  • Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
  • Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning
  • Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density
  • Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion
  • Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy
  • A survey of diagnosis, management, and grading of chronic GVHD
  • Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease
  • Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
  • Replicative senescence of mesenchymal stem cells: a continuous and organized process
  • Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease
  • Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study
  • Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
  • Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis
  • Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart
  • Mesenchymal stem cells are injured by complement after their contact with serum
  • Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice
  • Doubts over heart stem-cell therapy
  • Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy
  • Replicative senescence of mesenchymal stem cells: a continuous and organized process
  • Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes
  • Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
  • Galipeau, J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
  • Modification of mesenchymal stem cells for cardiac regeneration
  • Different facets of aging in human mesenchymal stem cells
  • Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy